A Phase II randomized clinical trial will evaluate a proprietary universal cancer vaccine, UV1, in patients with recurrent or metastatic head and neck cancer who will be treated with standard of care therapy pembrolizumab.
UV1 is a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase.
The trial will be conducted at ten sites across Germany and led by principal investigator Prof. Mascha Binder, M.D., Medical Director, and Head of the Immunological Tumor Group at University Medicine Halle, Germany.
Universal Cancer Vaccine Launches Phase 2 Clinical Trial
Buprenorphine Rx Fills for OUD Plateau During Pandemic
Cash-paid prescriptions declined significantly, but no significant changes seen in those paid by public or private insurance
Most Pregnant Women With SARS-CoV-2 Infection Are Asymptomatic
Patients who test positive for SARS-CoV-2 more likely to be Hispanic, report Spanish as primary language
Risk for Severe COVID-19 Not Increased for Children With Cancer
In children with cancer younger than 16, the estimated incidence of hospital-identified SARS-CoV-2 infection was 3 percent
Poll: Pandemic-Related Concerns Top of Mind for Parents
While the virus itself is not a top concern overall, impacts of COVID-19, including screen time and mental health, rate highly
Surprise Medical Bills Could Be Reduced by COVID-19 Relief Package
Main provisions of the legislation would take effect January 2022
Care Rationing Being Considered by California Hospitals
California has more than twice as many hospitalized COVID-19 patients as it did at its previous peak in July
European Union ApprovesĀ Pfizer COVID-19 Vaccine
Vaccine is already being given to high-risk people in the United States and Britain